Proto-oncogene Bmi-1 and head and neck cancer

[1]

Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.

[2]

[3]

Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie.Research progress of myeloid-derived suppressor cells in tumor angiogenesis[J]. Journal of International Oncology, 2024, 51(1): 50-54.

[4]

Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui.Role of ABRACL in the occurrence and development of malignant tumors[J]. Journal of International Oncology, 2023, 50(9): 544-547.

[5]

[6]

[7]

[8]

Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei.Current status of research on exosomes in malignancies[J]. Journal of International Oncology, 2023, 50(8): 484-488.

[9]

Ju Yifan, Xu Chenyang, Lei Dapeng.Research progress of pathomics in head and neck neoplasms[J]. Journal of International Oncology, 2023, 50(5): 294-298.

[10]

[11]

[12]

[13]

Li Lixi, Wen Tingyu, Guan Xiuwen, Zhai Jingtong, Ma Fei.Genetic susceptibility genes and clinical features of early-onset breast cancer[J]. Journal of International Oncology, 2022, 49(4): 206-209.

[14]

Zeng Yan, Luo Pan, Wang Ziqi, Wu Weili.Mechanism of drug induced ferroptosis in the treatment of head and neck tumors[J]. Journal of International Oncology, 2022, 49(3): 173-176.

[15]

Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng.Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(11): 665-670.

PDF